- Home
- ZURA vs ACRV Comparison
ZURA vs ACRV Comparison
Compare ZURA & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZURA
- ACRV
- Stock Information
- Founded
- ZURA 2022
- ACRV 2018
- Country
- ZURA United States
- ACRV United States
- Employees
- ZURA N/A
- ACRV 61
- Industry
- ZURA Biotechnology: Biological Products (No Diagnostic Substances)
- ACRV Medicinal Chemicals and Botanical Products
- Sector
- ZURA Health Care
- ACRV Health Care
- Exchange
- ZURA Nasdaq
- ACRV Nasdaq
- Market Cap
- ZURA 292.1M
- ACRV 203.9M
- IPO Year
- ZURA N/A
- ACRV 2022
- Fundamental
- Price
- ZURA $2.73
- ACRV $6.55
- Analyst Decision
- ZURA Buy
- ACRV Strong Buy
- Analyst Count
- ZURA 6
- ACRV 5
- Target Price
- ZURA $15.80
- ACRV $22.40
- AVG Volume (30 Days)
- ZURA 338.7K
- ACRV 46.3K
- Earning Date
- ZURA 11-07-2024
- ACRV 11-13-2024
- Dividend Yield
- ZURA N/A
- ACRV N/A
- EPS Growth
- ZURA N/A
- ACRV N/A
- EPS
- ZURA N/A
- ACRV N/A
- Revenue
- ZURA N/A
- ACRV N/A
- Revenue This Year
- ZURA N/A
- ACRV N/A
- Revenue Next Year
- ZURA N/A
- ACRV N/A
- P/E Ratio
- ZURA N/A
- ACRV N/A
- Revenue Growth
- ZURA N/A
- ACRV N/A
- 52 Week Low
- ZURA $2.00
- ACRV $3.19
- 52 Week High
- ZURA $6.35
- ACRV $11.90
- Technical
- Relative Strength Index (RSI)
- ZURA 26.08
- ACRV 34.32
- Support Level
- ZURA $2.78
- ACRV $6.11
- Resistance Level
- ZURA $3.38
- ACRV $6.68
- Average True Range (ATR)
- ZURA 0.35
- ACRV 0.49
- MACD
- ZURA -0.18
- ACRV -0.20
- Stochastic Oscillator
- ZURA 1.17
- ACRV 16.73
About ZURA Zura Bio Limited
Zura Bio Ltd is a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders.
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.